G1 Therapeutics buy melinda
Summary
This prediction ended on 22.01.19 with a price of €18.25. The BUY prediction by melinda for G1 Therapeutics performed very badly with a performance of -54.97%. melinda has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
G1 Therapeutics | 12.075% | 12.075% | 3.304% | -85.999% |
iShares Core DAX® | 1.395% | -0.272% | 17.642% | 15.576% |
iShares Nasdaq 100 | 2.287% | 6.912% | 37.651% | 51.525% |
iShares Nikkei 225® | 1.617% | 3.038% | 12.910% | 8.243% |
iShares S&P 500 | 0.659% | 3.687% | 29.434% | 44.236% |
Comments by melinda for this prediction
In the thread G1 Therapeutics diskutieren
SecteurRecherche biotechnologique et médicale Agenda 19/10 Présentation
G1 Therapeutics, Inc. develops drugs for cancer treatment.
It is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology.
The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Nombre d'employés : 44 personnes.